drugset / Trial / NCT00621296
Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C
Phase 2
Completed
15 enrolled
Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy and safety after administration of MP-424 to patients with chronic hepatitis C.
Timeline
- Start
- 2008-01
- Primary completion
- 2009-02
- Completion
- 2009-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telaprevir | Small molecule | 750 mg | Oral |